Vesilute
- Category
- Bioregulators
- Administration routes
- InjectableOral
- Regulatory status
- Not FDA-approved
What it is
A dipeptide bioregulator (Glu-Asp) marketed for bladder and prostate health, meant to normalize detrusor muscle function and reduce urinary tract inflammation. The case is almost entirely speculative: claims for overactive bladder and prostate symptoms rest on limited mechanistic work, with no independent human validation. There is essentially no human safety data, and supply is unregulated research-grade. Not FDA-approved; contraindicated in pregnancy.
Read Full recordStudied uses & evidence
Studied uses(5)
Normalization of detrusor contractility and bladder smooth muscle function
SpeculativeOne 1993 animal study tested a related prostate extract, not this specific dipeptide; mechanism-based only.
Improvement of overactive bladder symptoms in women with detrusor overactivity
SpeculativeNo published clinical trials or registered studies support this specific claim.
Tissue-specific gene expression regulation via epigenetic DNA interaction
LowMultiple studies show short peptides of this class binding DNA and altering transcription in cells.
Evidence limits
- Evidence Level
- Very Limited Evidence
The clinical evidence for Vesilute is extremely limited and relies substantially on studies of the related polypeptide extract Vezusten rather than the isolated Glu-Asp dipeptide. Human evidence cited here concerns Vezusten, not isolated Vesilute, and includes a 2022 placebo-controlled randomized trial as well as the 2024 cohort of 20 women with overactive bladder treated with intramuscular Vezusten injections, showing statistically significant improvements in urination frequency (14 to 11 per day, p<0.001), urge incontinence episodes (p=0.004), and maximum cystometric capacity (267 to 320 ml). Preclinical evidence demonstrates normalization of detrusor contractility in rat models with infravesical obstruction. The mechanistic rationale draws on the broader Khavinson short peptide framework, where dipeptides are shown to regulate gene expression through DNA interaction. Major limitations: the 2024 cohort was not randomized and was very small (n=20), the human studies used Vezusten (polypeptide extract) rather than the isolated Vesilute dipeptide, all research originates from Russian institutions, and no independent validation exists.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(5)
Risks = level of concern: High · Moderate · Low · Theoretical
Extremely limited clinical evidence and lack of independent validation
HighUnproven efficacy of the isolated dipeptide vs. polypeptide extract
HighUnregulated product quality (research-grade sources)
HighContraindicated in pregnancy and lactation
ModeratePossible mild side effects (theoretical and vendor-reported)
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.